Abiraterone Acetate and Radium-223 in Castrate-Resistant Prostate Cancer: Finding the Right Treatment at the Right Time - Charles Ryan

Chuck Ryan's presentation on Abriaterone Acetate and Radium-223 and finding the right treatment at the right time for the right patient.  This discussion is lead by reviewing a patient case study and the practical considerations in the use of novel hormonal agents in the post-ADT setting.  Dr. Ryan provides take home points for proactive metastatic castration-restistant prostate thearpy and benefits of radium-223 for life prolongation. 

Biography

Charles J. Ryan, MD
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe